Dual transgene expression by foamy virus vectors carrying an endogenous bidirectional promoter

Gene Therapy

Volumn 17, Issue 3, 2010, Pages 380-388

  Andrianaki, A ^a   Siapati, E K ^a   Hirata, R K ^b   Russell, D W ^b   Vassilopoulos, G ^a,c  

^a Biomedical Research Foundation   (Greece)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF THESSALY   (Greece)

Author keywords

Bidirectional promoter; FV; Gene transfer; Hematopoietic stem cells

Indexed keywords

ALPHA GALACTOSIDASE; CD34 ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN H2; NERVE GROWTH FACTOR RECEPTOR; SPUMA VIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; CELL TRANSPLANTATION; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENOME; HUMAN; HUMAN CELL; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; SPUMA VIRUS; STEM CELL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; X CHROMOSOME;

ALPHA-GALACTOSIDASE; ANIMALS; ANTIGENS, CD34; CHROMOSOMES, HUMAN, X; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP F-H; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MONOCYTES; PROMOTER REGIONS, GENETIC; SPUMAVIRUS; TRANSGENES;

HUMAN SPUMARETROVIRUS; MUS;

EID: 77949424086     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.147     Document Type: Article

References (39)

1. Sawai N, Zhou S, Vanin EF, Houghton P, Brent TP, Sorrentino BP. Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol Ther 2001; 3: 78-87.
2. Gerull S, Beard BC, Peterson LJ, Neff T, Kiem HP. In vivo selection and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs. Hum Gene Ther 2007; 18: 451-456.
3. Chinnasamy D, Milsom MD, Shaffer J, Neuenfeldt J, Shaaban AF, Margison GP et al. Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI. Virol J 2006; 3: 14.
4. Cai S, Ernstberger A, Wang H, Bailey BJ, Hartwell JR, Sinn AL et al. In vivo selection of hematopoietic stem cells transduced at a low multiplicity-of-infection with a foamy viral MGMT(P140K) vector. Exp Hematol 2008; 36: 283-292.
5. Persons DA, Allay ER, Sawai N, Hargrove PW, Brent TP, Hanawa H et al. Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood 2003; 102: 506-513.
6. Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 2000; 1: 376-382.
7. Hennecke M, Kwissa M, Metzger K, Oumard A, Kroger A, Schirmbeck R et al. Composition and arrangement of genes define the strength of IRES-driven translation in bicistronic mRNAs. Nucleic Acids Res 2001; 29: 3327-3334.
8. Kozak M. Alternative ways to think about mRNA sequences and proteins that appear to promote internal initiation of translation. Gene 2003; 318: 1-23.
9. Emerman M, Temin HM. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 1984; 39: 449-467.
10. Eszterhas SK, Bouhassira EE, Martin DI, Fiering S. Transcrip-tional interference by independently regulated genes occurs in any relative arrangement of the genes and is influenced by chromosomal integration position. Mol Cell Biol 2002; 22: 469-479.
11. Yu X, Zhan X, D'Costa J, Tanavde VM, Ye Z, Peng T et al. Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells. Mol Ther 2003; 7: 827-838.
12. Curtin JA, Dane AP, Swanson A, Alexander IE, Ginn SL. Bidirectional promoter interference between two widely used internal heterologous promoters in a late-generation lentiviral construct. Gene Therapy 2008; 15: 384-390.
13. Ryan MD, Drew J. Foot-and-mouth disease virus 2A oligopep-tide mediated cleavage of an artificial polyprotein. EMBO J 1994; 13: 928-933.
14. Furler S, Paterna JC, Weibel M, Bueler H. Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neurons. Gene Therapy 2001; 8: 864-873.
15. de Felipe P. Skipping the co-expression problem: the new 2A 'CHYSEL' technology. Genet Vaccines Ther 2004; 2: 13.
16. de Felipe P, Luke GA, Hughes LE, Gani D, Halpin C, Ryan MD. E unum pluribus: multiple proteins from a self-processing polyprotein. Trends Biotechnol 2006; 24: 68-75.
17. Amendola M, Venneri MA, Biffi A, Vigna E, Naldini L. Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol 2005; 23: 108-116.
18. Zhang F, Thornhill SI, Howe SJ, Ulaganathan M, Schambach A, Sinclair J et al. Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hemato-poietic cells. Blood 2007; 110: 1448-1457.
19. Adachi N, Lieber MR. Bidirectional gene organization: a common architectural feature of the human genome. Cell 2002; 109: 807-809.
20. Takai D, Jones PA. Origins of bidirectional promoters: computational analyses of intergenic distance in the human genome. Mol Biol Evol 2004; 21: 463-467.
21. Trinklein ND, Aldred SF, Hartman SJ, Schroeder DI, Otillar RP, Myers RM. An abundance of bidirectional promoters in the human genome. Genome Res 2004; 14: 62-66.
22. Guarguaglini G, Battistoni A, Pittoggi C, Di Matteo G, Di Fiore B, Lavia P. Expression of the murine RanBP1 and Htf9-c genes is regulated from a shared bidirectional promoter during cell cycle progression. Biochem J 1997; 325(Part 1): 277-286.
23. Ahn J, Gruen JR. The genomic organization of the histone clusters on human 6p213. Mamm Genome 1999; 10: 768-770.
24. Hansen JJ, Bross P, Westergaard M, Nielsen MN, Eiberg H, Borglum AD et al. Genomic structure of the human mitochon-drial chaperonin genes: HSP60 and HSP10 are localised head to head on chromosome 2 separated by a bidirectional promoter. Hum Genet 2003; 112: 71-77.
25. Greene WK, Sontani Y, Sharp MA, Dunn DS, Kees UR, Bellgard MI. A promoter with bidirectional activity is located between TLX1/HOX11 and a divergently transcribed novel human gene. Gene 2007; 391: 223-232.
26. Yang MQ, Elnitski LL. Prediction-based approaches to characterize bidirectional promoters in the mammalian genome. BMC Genomics 2008; 9(Suppl 1): S2.
27. Hung CF, Cheng TL, Wu RH, Teng CF, Chang WT. A novel bidirectional expression system for simultaneous expression of both the protein-coding genes and short hairpin RNAs in mammalian cells. Biochem Biophys Res Commun 2006; 339: 1035-1042.
28. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256.
29. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118: 3143-3150.
30. Josephson NC, Vassilopoulos G, Trobridge GD, Priestley GV, Wood BL, Papayannopoulou T et al. Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors. Proc Natl Acad Sci USA 2002; 99: 8295-8300.
31. Vassilopoulos G, Trobridge G, Josephson NC, Russell DW. Gene transfer into murine hematopoietic stem cells with helper-free foamy virus vectors. Blood 2001; 98: 604-609.
32. Trobridge G, Russell DW. Cell cycle requirements for transduc-tion by foamy virus vectors compared to those of oncovirus and lentivirus vectors. J Virol 2004; 78: 2327-2335.
33. Hendrie PC, Huo Y, Stolitenko RB, Russell DW. A rapid and quantitative assay for measuring neighboring gene activation by vector proviruses. Mol Ther 2008; 16: 534-540.
34. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
35. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-409.
36. Trobridge GD, Miller DG, Jacobs MA, Allen JM, Kiem HP, Kaul R et al. Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci USA 2006; 103: 1498-1503.
37. Gil A, Proudfoot NJ. Position-dependent sequence elements downstream of AAUAAA are required for efficient rabbit beta-globin mRNA 3 end formation. Cell 1987; 49: 399-406.
38. Vassilopoulos G, Josephson NC, Trobridge G. Development of foamy virus vectors. Methods Mol Med 2003; 76: 545-564.
39. Siapati EK, Bigger BW, Miskin J, Chipchase D, Parsley KL, Mitrophanous K et al. Comparison of HIV-and EIAV-based vectors on their efficiency in transducing murine and human hematopoietic repopulating cells. Mol Ther 2005; 12: 537-546.